← All trials
NCT03252600
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 25, 2017
- Primary completion
- Sep 30, 2019
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 53
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Wayne State UniversityLead sponsor
- Wayne State UniversityOverall official - principal investigator
- Wayne State UniversityReponsible party - principal investigator
- Multiple Myeloma Research ConsortiumCollaborator
- National Cancer Institute (NCI)Collaborator
- Wayne State UniversityOfficial
- Bristol-Myers SquibbCollaborator
- Wayne State UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.